中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 10
Oct.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(10): 2416-2421

Ischemic hepatitis: A severe liver disease that cannot be neglected

DOI: 10.3969/j.issn.1001-5256.2022.010.042

  • Department of Infectious Diseases, Chongqing Key Laboratory of Pediatrics, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, Children's Hospital of Chongqing Medical University, Chongqing 400014, China

More Information
  • Corresponding author: XU Hongmei, xuhongm0095@sina.com(ORCID: 0000-0002-7751-6756)
  • Received Date: 2022-03-12
  • Accepted Date: 2022-04-15
  • Published Date: 2022-10-20
    Abstract
  • Ischemic hepatitis is increasingly common in the intensive care unit and often has a poor prognosis. Due to the complex pathogenesis of ischemic hepatitis and a lack of specific clinical manifestations, auxiliary examination methods are limited and there are still no unified diagnostic criteria and treatment methods. Early identification and treatment of ischemic hepatitis is of particular importance. This article reviews the epidemiology, pathogenesis, clinical manifestations, auxiliary examination, diagnosis, and treatment of ischemic hepatitis and related research advances, in order to improve the awareness of this disease among clinicians and promote the timely diagnosis and treatment of this disease.

     

    • FullText(HTML)
  • loading
    • References(51)
  • [1]
    BIRGENS HS, HENRIKSEN J, MATZEN P, et al. The shock liver. Clinical and biochemical findings in patients with centrilobular liver necrosis following cardiogenic shock[J]. Acta Med Scand, 1978, 204(5): 417-421.
    [2]
    BYNUM TE, BOITNOTT JK, MADDREY WC. Ischemic hepatitis[J]. Dig Dis Sci, 1979, 24(2): 129-135. DOI: 10.1007/BF01324740.
    [3]
    GARLAND JS, WERLIN SL, RICE TB. Ischemic hepatitis in children: diagnosis and clinical course[J]. Crit Care Med, 1988, 16(12): 1209-1212. DOI: 10.1097/00003246-198812000-00006.
    [4]
    LIGHTSEY JM, ROCKEY DC. Current concepts in ischemic hepatitis[J]. Curr Opin Gastroenterol, 2017, 33(3): 158-163. DOI: 10.1097/MOG.0000000000000355.
    [5]
    BREU AC, PATWARDHAN VR, NAYOR J, et al. A multicenter study into causes of severe acute liver injury[J]. Clin Gastroenterol Hepatol, 2019, 17(6): 1201-1203. DOI: 10.1016/j.cgh.2018.08.016.
    [6]
    JONSDOTTIR S, ARNARDOTTIR MB, ANDRESSON JA, et al. Prevalence, clinical characteristics and outcomes of hypoxic hepatitis in critically ill patients[J]. Scand J Gastroenterol, 2022, 57(3): 311-318. DOI: 10.1080/00365521.2021.2005136.
    [7]
    TAPPER EB, SENGUPTA N, BONDER A. The incidence and outcomes of ischemic hepatitis: A systematic review with Meta-analysis[J]. Am J Med, 2015, 128(12): 1314-1321. DOI: 10.1016/j.amjmed.2015.07.033.
    [8]
    JUNG C, FUERNAU G, EITEL I, et al. Incidence, laboratory detection and prognostic relevance of hypoxic hepatitis in cardiogenic shock[J]. Clin Res Cardiol, 2017, 106(5): 341-349. DOI: 10.1007/s00392-016-1060-3.
    [9]
    van den BROECKE A, van COILE L, DECRUYENAERE A, et al. Epidemiology, causes, evolution and outcome in a single-center cohort of 1116 critically ill patients with hypoxic hepatitis[J]. Ann Intensive Care, 2018, 8(1): 15. DOI: 10.1186/s13613-018-0356-z.
    [10]
    LEE YI, KANG MG, KO RE, et al. The impact of hypoxic hepatitis on clinical outcomes after extracorporeal cardiopulmonary resuscitation[J]. J Clin Med, 2020, 9(9): 2994. DOI: 10.3390/jcm9092994.
    [11]
    CHOI SH, JANG HJ, SUH YJ, et al. Clinical implication of hypoxic liver injury for predicting hypoxic hepatitis and in-hospital mortality in ST elevation myocardial infarction patients[J]. Yonsei Med J, 2021, 62(10): 877-884. DOI: 10.3349/ymj.2021.62.10.877.
    [12]
    YAO JX, LYU L, LONG C, et al. Prevalence, risk factors, and prognosis of ischemic hepatitis during venous-arterial extracorporeal membrane oxygenation[J]. Int J Anesthesiol Resuscitation, 2017, 38(11): 987-992. DOI: org/ 10.1016/j.transproceed.2020.10.031.

    姚婧鑫, 吕琳, 龙村, 等. 体外膜氧合治疗期间缺血性肝炎发病率、危险因素及预后[J]. 国际麻醉学与复苏杂志, 2017, 38(11): 987-992. DOI: org/ 10.1016/j.transproceed.2020.10.031.
    [13]
    HUANG H, LI H, CHEN S, et al. Prevalence and characteristics of hypoxic hepatitis in COVID-19 patients in the intensive care unit: A first retrospective study[J]. Front Med (Lausanne), 2020, 7: 607206. DOI: 10.3389/fmed.2020.607206.
    [14]
    CAI HB, HUANG BX, ZHU ZS, et al. Analysis of clinical characteristics of hypoxic hepatitis in children[J]. Chin J Peds, 2016, 54(3): 201-204. DOI: 10.3760/cma.j.issn.0578-1310.2016.03.009.

    蔡华波, 黄宝兴, 朱忠生, 等. 儿童缺氧性肝炎临床特点分析[J]. 中华儿科杂志, 2016, 54(3): 201-204. DOI: 10.3760/cma.j.issn.0578-1310.2016.03.009.
    [15]
    PANWAR V, RANAWEERA P. Ischemic hepatitis secondary to hepatic artery steal in a patient with celiac artery stenosis and severe postural hypotension[J]. Catheter Cardiovasc Interv, 2011, 78(5): 799-801. DOI: 10.1002/ccd.22994.
    [16]
    HORVATITS T, DROLZ A, TRAUNER M, et al. Liver injury and failure in critical illness[J]. Hepatology, 2019, 70(6): 2204-2215. DOI: 10.1002/hep.30824.
    [17]
    WASEEM N, CHEN PH. Hypoxic hepatitis: A review and clinical update[J]. J Clin Transl Hepatol, 2016, 4(3): 263-268. DOI: 10.14218/JCTH.2016.00022.
    [18]
    LI DZ, YOU SL, LYU S, et al. Diagnosis and treatment of special subacute liver failure: A case report[J]. Chin Hepatol, 2021, 26(7): 819-821. DOI: 10.14000/j.cnki.issn.1008-1704.2021.07.030.

    李东泽, 游绍莉, 吕飒, 等. 1例特殊亚急性肝功能衰竭患者的诊治[J]. 肝脏, 2021, 26(7): 819-821. DOI: 10.14000/j.cnki.issn.1008-1704.2021.07.030.
    [19]
    KHAN H, PHILLIPOSE J, AHMED M, et al. Athlete's hepatitis in a young healthy marathon runner[J]. Case Rep Gastroenterol, 2018, 12(1): 176-181. DOI: 10.1159/000488446.
    [20]
    CIOBANU AO, GHERASIM L. Ischemic hepatitis-intercorrelated pathology[J]. Maedica (Bucur), 2018, 13(1): 5-11. DOI: 10.26574/maedica.2018.13.1.5
    [21]
    HENRION J. Ischemia/reperfusion injury of the liver: pathophysiologic hypotheses and potential relevance to human hypoxic hepatitis[J]. Acta Gastroenterol Belg, 2000, 63(4): 336-347.
    [22]
    MARUYAMA H, SHⅡNA S. Antioxidant therapy on ischemic hepatitis: here we are and where do we go?[J]. Hepatol Int, 2020, 14(4): 456-459. DOI: 10.1007/s12072-020-10044-y.
    [23]
    XU D, TIAN Y, XIA Q, et al. The cGAS-STING pathway: Novel perspectives in liver diseases[J]. Front Immunol, 2021, 12: 682736. DOI: 10.3389/fimmu.2021.682736.
    [24]
    RABIE MA, ZAKI HF, SAYED HM. Telluric acid ameliorates hepatic ischemia reperfusion-induced injury in rats: Involvement of TLR4, Nrf2, and PI3K/Akt signaling pathways[J]. Biochem Pharmacol, 2019, 168: 404-411. DOI: 10.1016/j.bcp.2019.08.001.
    [25]
    BUTLER DC, LEWIN DN, BATALIS NI. Differential diagnosis of hepatic necrosis encountered at autopsy[J]. Acad Forensic Pathol, 2018, 8(2): 256-295. DOI: 10.1177/1925362118782056.
    [26]
    RAURICH JM, LLOMPART-POU JA, FERRERUELA M, et al. Hypoxic hepatitis in critically ill patients: incidence, etiology and risk factors for mortality[J]. J Anesth, 2011, 25(1): 50-56. DOI: 10.1007/s00540-010-1058-3.
    [27]
    TAYLOR RM, TUJIOS S, JINJUVADIA K, et al. Short and long-term outcomes in patients with acute liver failure due to ischemic hepatitis[J]. Dig Dis Sci, 2012, 57(3): 777-785. DOI: 10.1007/s10620-011-1918-1.
    [28]
    ABOELSOUD MM, JAVAID AI, AL-QADI MO, et al. Hypoxic hepatitis-its biochemical profile, causes and risk factors of mortality in critically-ill patients: A cohort study of 565 patients[J]. J Crit Care, 2017, 41: 9-15. DOI: 10.1016/j.jcrc.2017.04.040.
    [29]
    JÄGER B, DROLZ A, MICHL B, et al. Jaundice increases the rate of complications and one-year mortality in patients with hypoxic hepatitis[J]. Hepatology, 2012, 56(6): 2297-2304. DOI: 10.1002/hep.25896.
    [30]
    PRIMA V, CAO M, SVETLOV SI. ASS and SULT2A1 are novel and sensitive biomarkers of acute hepatic injury-A comparative study in animal models[J]. J Liver, 2013, 2(1): 1000115. DOI: 10.4172/2167-0889.1000115.
    [31]
    HORVATITS T, KNEIDINGER N, DROLZ A, et al. Prognostic impact of ICG-PDR in patients with hypoxic hepatitis[J]. Ann Intensive Care, 2015, 5(1): 47. DOI: 10.1186/s13613-015-0092-6.
    [32]
    GHOSH A, ONSAGER C, MASON A, et al. The role of oxygen intake and liver enzyme on the dynamics of damaged hepatocytes: Implications to ischaemic liver injury via a mathematical model[J]. PLoS One, 2021, 16(4): e0230833. DOI: 10.1371/journal.pone.0230833.
    [33]
    GIANNINI EG, TESTA R, SAVARINO V. Liver enzyme alteration: a guide for clinicians[J]. CMAJ, 2005, 172(3): 367-379. DOI: 10.1503/cmaj.1040752.
    [34]
    Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.

    中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
    [35]
    LIU M, TAN W, YUAN W, et al. Development and validation of a diagnostic model to predict the risk of ischemic liver injury after Stanford A aortic dissection surgery[J]. Front Cardiovasc Med, 2021, 8: 701537. DOI: 10.3389/fcvm.2021.701537.
    [36]
    MAIWALL R, KUMAR A, BHADORIA AS, et al. Utility of N-acetylcysteine in ischemic hepatitis in cirrhotics with acute variceal bleed: a randomized controlled trial[J]. Hepatol Int, 2020, 14(4): 577-586. DOI: 10.1007/s12072-020-10013-5.
    [37]
    WANG G, LI JY, WENG YQ, et al. Protective effect of ulinastatin combined with dexmedetomidine on lung injury after cold ischemia-reperfusion in rats[J]. Eur Rev Med Pharmacol Sci, 2018, 22(17): 5712-5718. DOI: 10.26355/eurrev_201809_15839.
    [38]
    CHEN BH, LI WM. Effect of ulinastatin combined with ischemic preconditioning on hepatic ischemia-reperfusion injury in rats[J]. J Clin Hepatol, 2018, 34(2): 368-372. DOI: 10.3969/j.issn.1001-5256.2018.02.030.

    陈宝鹤, 李文美. 乌司他丁联合缺血预处理对大鼠肝缺血再灌注损伤的影响[J]. 临床肝胆病杂志, 2018, 34(2): 368-372. DOI: 10.3969/j.issn.1001-5256.2018.02.030.
    [39]
    ZHOU L, YANG X, SHU S, et al. Sufentanil protects the liver from ischemia/reperfusion-induced inflammation and apoptosis by inhibiting ATF4-induced TP53BP2 expression[J]. Inflammation, 2021, 44(3): 1160-1174. DOI: 10.1007/s10753-020-01410-x.
    [40]
    DENG J, FENG J, LIU T, et al. Beraprost sodium preconditioning prevents inflammation, apoptosis, and autophagy during hepatic ischemia-reperfusion injury in mice via the P38 and JNK pathways[J]. Drug Des Devel Ther, 2018, 12: 4067-4082. DOI: 10.2147/DDDT.S182292.
    [41]
    QIANG GH, WANG ZX, JI AL, et al. Sphingosine kinase 1 knockout alleviates hepatic ischemia/reperfusion injury by attenuating inflammation and oxidative stress in mice[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(3): 255-265. DOI: 10.1016/j.hbpd.2019.04.001.
    [42]
    ZHU P, DUAN L, CHEN J, et al. Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice[J]. Hum Gene Ther, 2011, 22(7): 853-864. DOI: 10.1089/hum.2010.145.
    [43]
    HARRELL CR, FELLABAUM C, JOVICIC N, et al. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome[J]. Cells, 2019, 8(5): 467. DOI: 10.3390/cells8050467.
    [44]
    LOU G, CHEN Z, ZHENG M, et al. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases[J]. Exp Mol Med, 2017, 49(6): e346. DOI: 10.1038/emm.2017.63.
    [45]
    CHAO TY, HSIEH CC, KUO YH, et al. Bracteanolide A abrogates oxidative stress-induced cellular damage and protects against hepatic ischemia and reperfusion injury in rats[J]. Food Sci Nutr, 2021, 9(9): 4758-4769. DOI: 10.1002/fsn3.2374.
    [46]
    LI J, GUO C, WU J. Fucoidan: Biological activity in liver diseases[J]. Am J Chin Med, 2020, 48(7): 1617-1632. DOI: 10.1142/S0192415X20500809.
    [47]
    LI J, ZHANG Q, LI S, et al. The natural product fucoidan ameliorates hepatic ischemia-reperfusion injury in mice[J]. Biomed Pharmacother, 2017, 94: 687-696. DOI: 10.1016/j.biopha.2017.07.109.
    [48]
    FAN X, LIN L, CUI B, et al. Therapeutic potential of genipin in various acute liver injury, fulminant hepatitis, NAFLD and other non-cancer liver diseases: More friend than foe[J]. Pharmacol Res, 2020, 159: 104945. DOI: 10.1016/j.phrs.2020.104945.
    [49]
    SHIN JK, LEE SM. Genipin protects the liver from ischemia/reperfusion injury by modulating mitochondrial quality control[J]. Toxicol Appl Pharmacol, 2017, 328: 25-33. DOI: 10.1016/j.taap.2017.05.002.
    [50]
    ZHOU YB, HUA J, QI LL, et al. Protective effect of curcumin pre-treatment on liver of acute ischemia-reperfusion model rats[J]. J Jilin Univ(Med Edit), 2020, 46(2): 297-301, 433. DOI: 10.13481/j.1671-587x.20200215.

    周亚宾, 华进, 戚伶俐, 等. 姜黄素预处理对急性缺血再灌注模型大鼠肝脏的保护作用[J]. 吉林大学学报(医学版), 2020, 46(2): 297-301, 433. DOI: 10.13481/j.1671-587x.20200215.
    [51]
    MI K, HUANG R. Protective effect of urolithin A pretreatment in a rat model of hepatic ischemia-reperfusion injury[J]. J Clin Hepatol, 2020, 36(8): 1783-1787. DOI: 10.3969/j.issn.1001-5256.2020.08.021.

    米凯, 黄锐. 尿石素A预处理对肝缺血再灌注损伤大鼠模型的保护作用[J]. 临床肝胆病杂志, 2020, 36(8): 1783-1787. DOI: 10.3969/j.issn.1001-5256.2020.08.021.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (962) PDF downloads(82) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return